dentalXrai has created innovative AI-based tools that enable the detection of dental pathologies and restorations with outstanding accuracy and speed. The start-up is a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH) after previous funding and support by Charité BIH Innovation with its Digital Health Accelerator Program. It has now been acquired by Align Technology, Inc., a global medical device company focused on dentistry. The company has recently announced X-Ray Insights, a tool based on dentalXrai technology and designed to streamline X-ray assessments, improve patient communication, and enhance the digital treatment experience.
Tube Pharmaceuticals, a spin-off from the Helmholtz Centre for Infection Research, has pioneered the use of tubulysins, a new class of natural products, as powerful anti-cancer agents. Their potency outperforms chemotherapeutics by several orders of magnitude. In late 2023, Tube was taken over by Oncomatryx, a global biopharmaceutical company developing next-generation precision drugs against the most invasive types of cancer. The transaction builds on a decade of highly successful collaboration between the partners that has resulted in promising clinical-stage antibody–cytolysin conjugates targeting the tumour microenvironment.
As technology transfer partner of the originating institutions, Ascenion has supported and held shares in dentalXrai and Tube Pharmaceuticals. The majority of (future) proceeds from the sale of Ascenion’s equity positions will go to the LifeScience Foundation, which will make the funds available for research projects at the endowing institutes.
Press release Align Technology
